Traci McCarty | Group VP, IR |
JJ Bienaimé | Chairman and CEO |
Jeff Ajer | EVP and Chief Commercial Officer |
Hank Fuchs | President, Worldwide R&D |
Greg Guyer | EVP and Chief Technical Officer |
Brian Mueller | EVP and CFO |
Salveen Richter | Goldman Sachs |
Geoff Meacham | Bank of America |
Phil Nadeau | Cowen and Company |
Jessica Fye | JPMorgan Chase |
Chris Raymond | Piper Sandler |
Matthew Harrison | Morgan Stanley |
Paul Matteis | Stifel |
Lachlan Hanbury-Brown | William Blair |
Josh Schimmer | Evercore ISI |
Welcome to the BioMarin Fourth Quarter Investor Update Call. Hosting the conference call today from BioMarin is Traci McCarty, Group Vice President of Investor Relations. Please go ahead, Traci.
Thank you, Paul, and thank you all for joining us today.
To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin’s financial performance, commercial products and potential future products in different areas of therapeutic research and development.